Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1962 Apr;41(4):896–916. doi: 10.1172/JCI104546

PATHOGENESIS OF THE COAGULATION DEFECT DEVELOPING DURING PATHOLOGICAL PLASMA PROTEOLYTIC (“FIBRINOLYTIC”) STATES. I. THE SIGNIFICANCE OF FIBRINOGEN PROTEOLYSIS AND CIRCULATING FIBRINOGEN BREAKDOWN PRODUCTS*

Anthony P Fletcher 1, Norma Alkjaersig 1, Sol Sherry 1
PMCID: PMC290991  PMID: 13893560

Full text

PDF
896

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ABLONDI F. B., HAGAN J. J., PHILIPS M., DE RENZO E. C. Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by 6-aminocaproic acid. Arch Biochem Biophys. 1959 May;82(1):153–160. doi: 10.1016/0003-9861(59)90100-6. [DOI] [PubMed] [Google Scholar]
  2. ABOULKER P., SOULIER J. P., LARRIEU M. J., WARTELLE O. Syndrome hémorragique avec fibrinolyse associé au cancer de la prostate. Presse Med. 1955 Mar 9;63(18):353–354. [PubMed] [Google Scholar]
  3. ALAGILLE D., SOULIER J. P. Action des enzymes protéolytiques sur le sang total in vitro; modifications des facteurs de coagulation et du complément. Sem Hop. 1956 Jan 30;32(7):355–359. [PubMed] [Google Scholar]
  4. ALKJAERSIG N., FLETCHER A. P., SHERRY S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization. J Clin Invest. 1962 Apr;41:917–934. doi: 10.1172/JCI104547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. ALKJAERSIG N., FLETCHER A. P., SHERRY S. The activation of human plasminogen. I. Spontaneous activation in glycerol. J Biol Chem. 1958 Jul;233(1):81–85. [PubMed] [Google Scholar]
  6. ALKJAERSIG N., FLETCHER A. P., SHERRY S. The mechanism of clot dissolution by plasmin. J Clin Invest. 1959 Jul;38(7):1086–1095. doi: 10.1172/JCI103885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. ALKJAERSIG N., FLETCHER A. P., SHERRY S. xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem. 1959 Apr;234(4):832–837. [PubMed] [Google Scholar]
  8. BEAUMONT J. L., BEAUMONT V., DOMART A. Recherches sur l'activité fibrinolytique spontanée du plasma dans les cirrhoses du foie. Rev Fr Etud Clin Biol. 1956 Jun;1(6):667–673. [PubMed] [Google Scholar]
  9. COON W. W., DUFF I. F. Effects of intravenous human plasmin on the blood clotting mechanism of the dog. J Lab Clin Med. 1958 Mar;51(3):381–385. [PubMed] [Google Scholar]
  10. DILLARD G. H. L., CHANUTIN A. The protease and antiprotease of plasmas of patients with cancer and other diseases. Cancer Res. 1949 Nov;9(11):665–668. [PubMed] [Google Scholar]
  11. DONALDSON V. H. Effect of plasmin in vitro on clotting factors in plasma. J Lab Clin Med. 1960 Oct;56:644–651. [PubMed] [Google Scholar]
  12. EDSALL J. T., LEVER W. F. Effects of ions and neutral molecules on fibrin clotting. J Biol Chem. 1951 Aug;191(2):735–756. [PubMed] [Google Scholar]
  13. FLETCHER A. P., ALKJAERSIG N., SHERRY S. The clearance of heterologous protein from the circulation of normal and immunized man. J Clin Invest. 1958 Sep;37(9):1306–1315. doi: 10.1172/JCI103719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. FLETCHER A. P., ALKJAERSIG N., SHERRY S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest. 1959 Jul;38(7):1096–1110. doi: 10.1172/JCI103886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. FLETCHER A. P., SHERRY S., ALKJAERSIG N., SMYRNIOTIS F. E., JICK S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest. 1959 Jul;38(7):1111–1119. doi: 10.1172/JCI103887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. GITLIN D., BORGES W. H. Studies on the metabolism of fibrinogen in two patients with congenital afibrinogenemia. Blood. 1953 Aug;8(8):679–686. [PubMed] [Google Scholar]
  17. INGRAM G. I., PINNIGER J. L., VALLET L. Survival in an afibrinogenaemic subject of fibrinogen prepared from "time-expired" blood. Lancet. 1960 Jan 16;1(7116):135–137. doi: 10.1016/s0140-6736(60)90055-6. [DOI] [PubMed] [Google Scholar]
  18. JOHNSON A. J., McCARTY W. R. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest. 1959 Sep;38:1627–1643. doi: 10.1172/JCI103941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. KEKWICK R. A., MACKAY M. E., NANCE M. H., RECORD B. R. The purification of human fibrinogen. Biochem J. 1955 Aug;60(4):671–683. doi: 10.1042/bj0600671b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. KWAAN H. C., MCFADZEAN A. J., COOK J. On plasma fibrinolytic activity in cryptogenetic splenomegaly. Scott Med J. 1957 Apr;2(4):137–150. doi: 10.1177/003693305700200402. [DOI] [PubMed] [Google Scholar]
  21. LEVER W. F., GURD F. R. N., UROMA E., BROWN R. K., BARNES B. A., SCHMID K., SCHULTZ E. L. Chemical, clinical and immunological studies on the products of human plasma fractionation XL. Quantitative separation and determination of the protein components in small amounts of normal human plasma. J Clin Invest. 1951 Jan;30(1):99–111. doi: 10.1172/JCI102423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. LEWIS J. H., FERGUSON E. E., SCHOENFELD C. Studies concerning the turnover of fibrinogen I-131 in the dog. J Lab Clin Med. 1961 Aug;58:247–258. [PubMed] [Google Scholar]
  23. LEWIS J. H., HOWE A. C., FERGUSON J. H. Thrombin formation; effects of lysin (fibrinolysin, plasmin) on prothrombin, Ac-globulin and tissue thromboplastin. J Clin Invest. 1949 Nov;28(6 Pt 2):1507–1510. doi: 10.1172/JCI102216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. MARGOLIUS A., Jr, JACKSON D. P., RATNOFF O. D. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 1961 May;40:145–202. [PubMed] [Google Scholar]
  25. MCNICOL G. P., FLETCHER A. P., ALKJAERSIG N., SHERRY S. Impairment of hemostasis in the urinary tract: the role of urokinase. J Lab Clin Med. 1961 Jul;58:34–46. [PubMed] [Google Scholar]
  26. MONKHOUSE F. C., MILOJEVIC S. Changes in fibrinogen level after infusion of thrombin and thromboplastin. Am J Physiol. 1960 Dec;199:1165–1168. doi: 10.1152/ajplegacy.1960.199.6.1165. [DOI] [PubMed] [Google Scholar]
  27. NIEWIAROWSKI S., KOWALSKI E. Unnouvel anticoagulant dérivé du fibrinogène. Rev Hematol. 1958 Jul-Sep;13(3):320–328. [PubMed] [Google Scholar]
  28. NILSSON I. M., SJOERDSMA A., WALDENSTROM J. Antifibrinolytic activity and metabolism of 6-aminocaproic acid in man. Lancet. 1960 Jun 18;1(7138):1322–1326. doi: 10.1016/s0140-6736(60)92305-9. [DOI] [PubMed] [Google Scholar]
  29. PHILLIPS L. L. Etiology of afibrinogenemia: fibrinogenolytic and fibrinolytic phenomena. Ann N Y Acad Sci. 1959 Jan 9;75:676–684. doi: 10.1111/j.1749-6632.1959.tb44582.x. [DOI] [PubMed] [Google Scholar]
  30. PRITCHARD J. A., WRIGHT M. R. Pathogenesis of hypofibrinogenemia in placental abruption. N Engl J Med. 1959 Jul 30;261(5):218–222. doi: 10.1056/NEJM195907302610502. [DOI] [PubMed] [Google Scholar]
  31. RATNOFF O. D., CONLEY C. L. Studies on afibrinogenemia. II. The defibrinating effect on dog blood of intravenous injection of thromboplastic material. Bull Johns Hopkins Hosp. 1951 May;88(5):414–424. [PubMed] [Google Scholar]
  32. RATNOFF O. D., HOLLAND T. R. Coagulation components in normal and abnormal pregnancies. Ann N Y Acad Sci. 1959 Jan 9;75:626–633. doi: 10.1111/j.1749-6632.1959.tb44580.x. [DOI] [PubMed] [Google Scholar]
  33. RATNOFF O. D., MENZIE C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med. 1951 Feb;37(2):316–320. [PubMed] [Google Scholar]
  34. RATNOFF O. D. Studies on a proteolytic enzyme in human plasma. IX. Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma. J Clin Invest. 1953 Jun;32(6):473–479. doi: 10.1172/JCI102762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. RATNOFF O. D. Studies on a proteolytic enzyme in human plasma. VII. A fatal hemorrhagic state associated with excessive plasma proteolytic activity in a patient undergoing surgery for carcinoma of the head of the pancreas. J Clin Invest. 1952 May;31(5):521–528. doi: 10.1172/JCI102636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. SAWYER W. D., ALKJAERSIG N., FLECTCHER A. P., SHERRY S. A comparison of the fibrinolytic and fibrinogenolytic effects of plasminogen activators and proteolytic enzymes in plasma. Thromb Diath Haemorrh. 1960 Dec 15;5:149–161. [PubMed] [Google Scholar]
  37. SAWYER W. D., FLETCHER A. P., ALKJAERSIN N., SHERRY S. Studies on the thrombolytic activity of human plasma. J Clin Invest. 1960 Feb;39:426–434. doi: 10.1172/JCI104054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. SCHNEIDER C. L. Etiology of fibrinopenia: fibrination defibrination. Ann N Y Acad Sci. 1959 Jan 9;75:634–675. doi: 10.1111/j.1749-6632.1959.tb44581.x. [DOI] [PubMed] [Google Scholar]
  39. SCOTT E. V., MATTHEWS W. F., BUTTERWORTH C. E., Jr, FROMMEYER W. B., Jr Abnormal plasma proteolytic activity; diagnosis and treatment. Surg Gynecol Obstet. 1954 Dec;99(6):679–688. [PubMed] [Google Scholar]
  40. SHARP A. A., HOWIE B., BIGGS R., METHUEN D. T. Defibrination syndrome in pregnancy: value of various diagnostic tests. Lancet. 1958 Dec 20;2(7060):1309–1312. doi: 10.1016/s0140-6736(58)90579-8. [DOI] [PubMed] [Google Scholar]
  41. SHERRY S., FLETCHER A. P., ALKJAERSIG N. Fibrinolysis and fibrinolytic activity in man. Physiol Rev. 1959 Apr;39(2):343–382. doi: 10.1152/physrev.1959.39.2.343. [DOI] [PubMed] [Google Scholar]
  42. SHERRY S., LINDEMEYER R. I., FLETCHER A. P., ALKJAERSIG N. Studies on enhanced fibrinolytic activity in man. J Clin Invest. 1959 May;38(5):810–822. doi: 10.1172/JCI103863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. SHERRY S., TROLL W., GLUECK H. Thrombin as a proteolytic enzyme. Physiol Rev. 1954 Oct;34(4):736–741. doi: 10.1152/physrev.1954.34.4.736. [DOI] [PubMed] [Google Scholar]
  44. SHERRY S. The fibrinolytic activity of streptokinase activated human plasmin. J Clin Invest. 1954 Jul;33(7):1054–1063. doi: 10.1172/JCI102973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. SOULIER J. P., ALAGILLE D., LARRIEU M. J. Modifications in vivo des facteurs de coagulation dans les fibrinolyses; valeur du déficit en proaccélérine pour le diagnostic des protéolyses frustes ou latentes. Sem Hop. 1956 Jan 30;32(7):359–366. [PubMed] [Google Scholar]
  46. SOULIER J. P., MATHEY J., LE BOLLOCK A. G., DAUMET P., FAYET H. Syndromes hémorragiques mortels avec incoagulabilité totale par défibrination et avec fibrinolyse. I. Au cours des exérèses pulmonaires. Rev Hematol. 1952;7(1):30–47. [PubMed] [Google Scholar]
  47. Seegers W. H., Loomis E. C. Prothrombin and Fibrinolysin. Science. 1946 Nov 15;104(2707):461–462. doi: 10.1126/science.104.2707.461. [DOI] [PubMed] [Google Scholar]
  48. TAGNON H. J., WHITMORE W. F., Jr, SCHULMAN P., KRAVITZ S. C. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate. Cancer. 1953 Jan;6(1):63–67. doi: 10.1002/1097-0142(195301)6:1<63::aid-cncr2820060105>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  49. TRIANTAPHYLLOPOULOS D. C. Anticoagulant effect of incubated fibrinogen. Can J Biochem Physiol. 1958 Mar;36(3):249–259. [PubMed] [Google Scholar]
  50. TRIANTAPHYLLOPOULOS D. C. Effects of intravenous injections of the anticoagulant fraction of incubated fibrinogen on blood coagulation. Can J Biochem Physiol. 1960 Aug;38:909–918. [PubMed] [Google Scholar]
  51. TRIANTAPHYLLOPOULOS D. C. Nature of the thrombin-inhibiting effect of incubated fibrinogen. Am J Physiol. 1959 Sep;197:575–579. doi: 10.1152/ajplegacy.1959.197.3.575. [DOI] [PubMed] [Google Scholar]
  52. TROLL W., SHERRY S. The activation of human plasminogen by streptokinase. J Biol Chem. 1955 Apr;213(2):881–891. [PubMed] [Google Scholar]
  53. TURPINI R., STEFANINI M. The nature and mechanism of the hemostatic breakdown in the course of experimental hemorrhagic shock. J Clin Invest. 1959 Jan 1;38(1 Pt 1):53–65. doi: 10.1172/JCI103795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. VOLWILER W., GOLDSWORTHY P. D., MACMARTIN M. P., WOOD P. A., MACKAY I. R., FREMONT-SMITH K. Biosynthetic determination with radioactive sulfur of turn-over rates of various plasma proteins in normal and cirrhotic man. J Clin Invest. 1955 Jul;34(7 Pt 1):1126–1146. doi: 10.1172/JCI103162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. VON KAULLA K. N., SWAN H. Clotting deviations in man during cardiac bypass: fibrinolysis and circulating anticoagulant. J Thorac Surg. 1958 Oct;36(4):519–530. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES